DULOXETIN COMPOSITION
    1.
    发明申请
    DULOXETIN COMPOSITION 审中-公开
    DULOXETIN组合物

    公开(公告)号:US20110008439A1

    公开(公告)日:2011-01-13

    申请号:US12521410

    申请日:2007-12-21

    IPC分类号: A61K9/14 A61K31/381

    摘要: The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt.

    摘要翻译: 本发明涉及包含度洛西汀或其药学上可接受的盐的稳定药物颗粒组合物和制备该组合物的方法。 特别地,组合物包含度洛西汀盐酸盐和包含水溶性无机盐的分离层。

    Pharmaceutical composition
    2.
    发明申请
    Pharmaceutical composition 审中-公开
    药物组成

    公开(公告)号:US20090093499A1

    公开(公告)日:2009-04-09

    申请号:US12158413

    申请日:2006-12-18

    IPC分类号: A61K31/505 A61P3/06

    摘要: A chemically stable formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules has been developed using the substances which stabilize against formation of degradation products: lactone and oxidation product.

    摘要翻译: (E)-7- [4-(4-氟苯基)-6-异丙基-2- [甲基(甲基磺酰基)氨基]嘧啶-5-基] - (3R,5S) 二羟基庚-6-烯酸或其药学上可接受的盐用于口服使用,例如片剂,胶囊,粉剂,颗粒剂,其使用稳定反应形成降解产物的物质:内酯和氧化产物。